Chagas disease in the immunosuppressed host
Caryn Berna b c d e✉
- aPrevention and Public Health Group, Global Health Sciences, Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco, California 94105, USA. Caryn.Bern@UCSF.edu
- bPrevention and Public Health Group, Global Health Sciences, Department of Epidemiology and Biostatistics University of California, San Francisco San Francisco, California, USA
- ce-mail: [email protected]
- dfax: +1 415 597 8299
- eto Caryn Bern, MD, MPH, Global Health Sciences, University of California, San Francisco, 50 Beale Street Suite 1200, San Francisco, CA 94105, USA. Tel: +1 415 597 8210
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
PURPOSE OF REVIEW: This review examines recent literature on Chagas disease in the immunosuppressed host. RECENT FINDINGS: Chagas disease in immunosuppressed patients may represent acute transmission in an organ recipient, or reactivation of chronic infection in an HIV-infected individual or patient receiving cardiac transplantation for Chagas cardiomyopathy. Transplantation of the kidney or liver from an infected donor resulted in transmission in 18-19 and 29%, respectively. Prospective monitoring usually detects acute infection before symptom onset; early treatment is highly effective. In heart transplant patients, reactivation symptoms include fever, myocarditis and skin lesions, and may mimic rejection. Approximately 20% of HIV- Trypanosoma cruzi infected patients experience reactivation; manifestations include meningoencephalitis and/or myocarditis. SUMMARY: Transplantation of the heart from a T. cruzi-infected donor is contraindicated; use of other organs can be considered. Guidelines recommend prospective monitoring rather than prophylactic treatment in recipients. Posttransplant monitoring for acute infection or reactivation relies on PCR, culture and microscopy of blood specimens regularly for at least 6 months. Treatment employs standard courses of benznidazole or nifurtimox, and immune reconstitution for the HIV-coinfected patient. Case reports suggest some HIV-T. cruzi-infected patients may benefit from secondary prophylaxis, but more data are needed to determine efficacy and specific regimens.
TL;DRTransplantation of the heart from a T. cruzi-infected donor is contraindicated; use of other organs can be considered and case reports suggest some HIV–T.cruzi- infected patients may benefit from secondary prophylaxis, but more data are needed to determine efficacy and specific regimens. (Semantic Scholar)